De Novo device
Advisor Pro Platform
DreaMed Diabetes, Ltd. · Insulin Pump Therapy Adjustment Calculator For Healthcare Professionals (QCC, Class II) · First FDA decision Jun 12, 2018, newest Sep 28, 2021Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
De Novo pathway
Device trials
8
Naming "Advisor Pro"
MAUDE reports
0
Brand "Advisor Pro", since 2015
PubMed studies
6
Mentioning "Advisor Pro"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Advisor Pro Platform510(k)
K210561 · Decided Sep 28, 2021 · 215 days after receipt
Device type: Insulin Pump Therapy Adjustment Calculator For Healthcare Professionals (QCC) · Laboratory Medicine & Pathology
- DreaMed Advisor Pro510(k)
K201476 · Decided Aug 28, 2020 · 86 days after receipt
Device type: Insulin Pump Therapy Adjustment Calculator For Healthcare Professionals (QCC) · Laboratory Medicine & Pathology
- DreaMed Advisor Pro510(k)
K191370 · Decided Jul 18, 2019 · 57 days after receipt
Device type: Insulin Pump Therapy Adjustment Calculator For Healthcare Professionals (QCC) · Laboratory Medicine & Pathology
- DreaMed Advisor ProNew device typeDe Novo
DEN170043 · Decided Jun 12, 2018 · 299 days after receipt
Device type: Insulin Pump Therapy Adjustment Calculator For Healthcare Professionals (QCC) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Outpatient Intravenous Insulin Treatment (Therapy)National analysisReview closedCAG-00410NUpdated Sep 18, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Advisor Pro", any status and sponsor, newest update first.
- The Advisor Pro Direct StudyPivotal-lookingTerminated
Rabin Medical CenterAcademic, hospital or other
NCT03774069 · 100 participants · Start Dec 1, 2020 · Primary completion Dec 1, 2023
Device: DreaMed Advisor Pro · For: Type 1 Diabetes Mellitus
Sites: Petah Tikva, Israel
Pack HealthNot on our public-company list
NCT05956457 · 100 participants (planned) · Start Sep 15, 2023 · Primary completion May 31, 2026
Device: Fitbit · For: Multiple Myeloma; Relapsed Hematologic Malignancy
Sites: Seattle, Washington
Rabin Medical CenterAcademic, hospital or other
NCT04653961 · 48 participants (planned) · Start Jun 1, 2020 · Primary completion Oct 2025
Device: DreaMed Advisor Pro DSS-MDI algorithm · For: Type1diabetes
Sites: Petah Tikva, Israel · 2 sites in all
Rabin Medical CenterAcademic, hospital or other
NCT04271228 · 70 participants · Start Feb 15, 2020 · Primary completion Jan 19, 2022
Device: DreaMed Advisor Pro · For: Type 1 Diabetes
Sites: Petah Tikva, Israel
Yale UniversityAcademic, hospital or other
NCT04904718 · 0 participants · Start Dec 2021 · Primary completion Dec 2021
Device: DreaMed Advisor Pro · For: Type1diabetes
DreaMed DiabetesNot on our public-company list
NCT04043260 · 35 participants · Start Nov 27, 2019 · Primary completion Feb 28, 2021
Device: Advisor Pro · For: Insulin-dependent Diabetes Mellitus; Diabetes Mellitus, Type 1
Sites: Petah Tikva, Israel
- Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro StudyPivotal-lookingCompleted
Rabin Medical CenterAcademic, hospital or other
NCT03003806 · 122 participants · Start Oct 2, 2017 · Primary completion Nov 10, 2019
Device: DreaMed Advisor Pro · For: Type1 Diabetes Mellitus
Sites: Aurora, Colorado; New Haven, Connecticut; Gainesville, Florida · 7 sites in all
Rabin Medical CenterAcademic, hospital or other
NCT02617160 · 50 participants · Start May 2016 · Primary completion Dec 2018
Device: MD-Logic Pump Advisor · For: Type 1 Diabetes
Sites: Petah Tikva, Israel
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Advisor Pro", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QCC
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Advisor Pro"[tiab]. The summary above synthesizes these.
- Adjustment of Insulin Pump Settings in Type 1 Diabetes Management: Advisor Pro Device Compared to Physicians' Recommendations.
Nimri R, Oron T, Muller I, et al. · J Diabetes Sci Technol · 2022
- Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians.
Nimri R, Dassau E, Segall T, et al. · Diabetes Obes Metab · 2018
- United States Department of Agriculture-Agricultural Research Service stored-grain areawide integrated pest management program.
Flinn PW, Hagstrum DW, Reed C, et al. · Pest Manag Sci · 2003
- Predicting stored grain insect population densities using an electronic probe trap.
Flinn PW, Opit GP, Throne JE · J Econ Entomol · 2009
- Use of patient education and monitoring software in community pharmacies.
Miller LG · J Am Pharm Assoc (Wash) · 1997Research Support, U.S. Gov't, Non-P.H.S.
- Development and Validation of an Integrated Artificial Intelligence-Powered Clinical Decision Support Application for Cardiac Critical Care: Combining Coagulation Management, Blood Gas Analysis, Mechanical Ventilation, Hemodynamic Assessment, and Extracorporeal Membrane Oxygenation.
El-Sonbaty AI · J Cardiothorac Vasc Anesth · 2026Validation Study
Other devices of this type
Also filed under product code QCC.
- endo.digital PlatformDreaMed Diabetes, Ltd. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.